Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 2015;149(7):1731–41. e3.
Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949–58.
Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2017;66(6):1075–82.
Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119(3):654–60.
Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. Aliment Pharmacol Ther. 2014;39(3):312–21.
Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2019;4(9):675–85.
Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–e1143.
Tillisch K, Mayer Ea Fau – Gupta A, Gupta A, Fau – Gill Z, Gill Z, Fau – Brazeilles R, Brazeilles R. Fau – Le Nevé B, Le Nevé B Fau – van Hylckama Vlieg JET, Brain Structure and Response to Emotional Stimuli as Related to Gut Microbial Profiles in Healthy Women. (1534–7796 (Electronic)).
Lerner A, Neidhöfer S, Matthias T. The Gut Microbiome Feelings of the Brain: A Perspective for Non-Microbiologists. LID – 10.3390/microorganisms5040066 doi] LID – 66. (2076–2607 (Print)).
Foster JA. Gut feelings: bacteria and the brain. (1524–6205 (Print)).
Margolis KG, Cryan JF, Mayer EA. The microbiota-gut-brain axis: from motility to mood. Gastroenterology. 2021;160:1486–501.
Dinan TG, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006;130:304–11.
Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology. 2011;140:761–5.
Tanaka Y, et al. Diferential activation in amygdala and plasma noradrenaline during colorectal distention by administration of corticotropin-releasing hormone between healthy individuals and patients with irritable bowel syndrome. PLoS ONE. 2016;11:e0157347.
Kennedy PJ, et al. Gut memories: towards a cognitive neurobiology of irritable bowel syndrome. Neurosci Biobehav Rev. 2012;36:310–40.
Parker CH, et al. The role of resilience in irritable bowel syndrome, other chronic gastrointestinal conditions, and the general population. Clin Gastroenterol Hepatol. 2021;19:2541–e25501.
Park SH, et al. Resilience is decreased in irritable bowel syndrome and associated with symptoms and cortisol response. Neurogastroenterol Motil. 2018. https://doi.org/10.1111/nmo.13155.
Waters RP, et al. Evidence for the role of corticotropin-releasing factor in major depressive disorder. Neurosci Biobehav Rev. 2015;58:63–78.
McGuinness AJ, et al. A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. Mol Psychiatry. 2022;27:1920–35.
Simpson CA, Mu A, Haslam N, Schwarz OS, Simmons JG. Feeling down? A systematic review of the gut microbiota in anxiety/depression and irritable bowel syndrome. J Afect Dis. 2020;266:429–46.
Tap J, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152:111–e1238.
Kelly JR, et al. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res. 2016;82:109–18.
De Palma G, et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med. 2017;9:eaaf6397.
Simpson CA, Mu A, Haslam N, Schwartz OS, Simmons JG. Feeling down? A systematic review of the gut microbiota in anxiety/depression and irritable bowel syndrome. (1573–2517 (Electronic)).
Liu Y, Zhang L, Wang X, Wang Z, Zhang J, Jiang R et al. Similar fecal microbiota signatures in patients with diarrhea-predominant irritable bowel syndrome and patients with Depression. (1542–7714 (Electronic)).
Tang HY, Jiang AJ, Wang XY, Wang H, Guan YY, Li F, et al. Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review. Ann Transl Med. 2021;9(14):1187.
Menees S, Chey W. The gut microbiome and irritable bowel syndrome. F1000Res. 2018;7.
Foxx-Orenstein AE, Chey WD. Manipulation of the gut microbiota as a Novel Treatment Strategy for Gastrointestinal disorders. Am J Gastroenterol Supplements. 2012;1(1):41–6.
Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107(1):28–35. quiz 6.
Dionne J, Ford AC, Yuan Y, Chey WD, Lacy BE, Saito YA, et al. A systematic review and Meta-analysis evaluating the efficacy of a gluten-free Diet and a low FODMAPs Diet in treating symptoms of irritable bowel syndrome. Am J Gastroenterol. 2018;113(9):1290–300.
Goldenberg D, Merrick S. B. The role of faecal microbiota transplantation: looking beyondClostridioides difficileinfection. Therapeutic Adv Infect Disease. 2021;8.
Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ. Clinical application and potential of fecal microbiota transplantation. Annu Rev Med. 2019;70:335–51.
Zhao HJ, Zhang XJ, Zhang NN, Yan B, Xu KK, Peng LH, et al. Fecal microbiota transplantation for patients with irritable bowel syndrome: a Meta-analysis of Randomized controlled trials. Front Nutr. 2022;9:890357.
Abdelghafar YA, AbdelQadir YH, Motawea KR, Nasr SA, Omran HAM, Belal MM, et al. Efficacy and safety of fecal microbiota transplant in irritable bowel syndrome: an update based on meta-analysis of randomized control trials. Health Sci Rep. 2022;5(5):e814.
Samuthpongtorn C, Kantagowit P, Pittayanon R, Patcharatrakul T, Gonlachanvit S. Fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Front Med (Lausanne). 2022;9:1039284.
El-Salhy M, Hatlebakk JG, Gilja OH, Brathen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859–67.
van Veldhuyzen SJ, Talley Nj Fau -, Bytzer P, Bytzer P, Fau – Klein KB et al. Design of treatment trials for functional gastrointestinal disorders. (0017-5749 (Print)).
Irvine EJ, Tack J, Crowell MD, Gwee KA, Ke M, Schmulson MJ et al. Design of treatment trials for Functional Gastrointestinal disorders. (1528-0012 (Electronic)).
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in Meta-analyses. BMJ. 2003;327(7414):557–60. 10.1136/ bmj.327.7414.557.
El-Salhy M, Winkel R, Casen C, Hausken T, Gilja OH, Hatlebakk JG. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at 3 years after transplantation. Gastroenterology. 2022;163(4):982–94. e14.
Johnsen PH, Hilpusch F, Valle PC, Goll R. The effect of fecal microbiota transplantation on IBS related quality of life and fatigue in moderate to severe non-constipated irritable bowel: secondary endpoints of a double blind, randomized, placebo-controlled trial. EBioMedicine. 2020;51:102562.
Johnsen PH, Hilpusch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17–24.
Halkjaer SI, Christensen AH, Lo BZS, Browne PD, Gunther S, Hansen LH, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107–15.
Holster S, Lindqvist CM, Repsilber D, Salonen A, de Vos WM, Konig J, et al. The Effect of Allogenic Versus Autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome: a randomized controlled study. Clin Transl Gastroenterol. 2019;10(4):e00034.
Holvoet T, Joossens M, Vazquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled Randomized Trial. Gastroenterology. 2021;160(1):145–57. e8.
Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillila M, Punkkinen J, et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Aliment Pharmacol Ther. 2020;51(12):1321–31.
Lin H, Guo Q, Wen Z, Tan S, Chen J, Lin L, et al. The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors. Microb Cell Fact. 2021;20(1):233.
Wu J, Lv L, Wang C. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a Meta-analysis of Randomized controlled trials. Front Cell Infect Microbiol. 2022;12:827395.
Jalanka J, Mattila E, Jouhten H, Hartman J, de Vos WM, Arkkila P, et al. Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. BMC Med. 2016;14(1):155.
Cui J, Lin Z, Tian H, Yang B, Zhao D, Ye C, et al. Long-term Follow-Up results of fecal microbiota transplantation for irritable bowel syndrome: a Single-Center, Retrospective Study. Front Med (Lausanne). 2021;8:710452.
Schmidt C, Grunert PC, Stallmach A. An update for pharmacologists on New Treatment options for Inflammatory Bowel Disease: the clinicians’ perspective. Front Pharmacol. 2021;12:655054.
Madsen AMA, Halkjaer SI, Christensen AH, Gunther S, Browne PD, Kallemose T, et al. The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: results from a randomised, double-blind, placebo-controlled study. Scand J Gastroenterol. 2021;56(7):761–9.
Browne PD, Cold F, Petersen AM, Halkjaer SI, Christensen AH, Gunther S, et al. Engraftment of strictly anaerobic oxygen-sensitive bacteria in irritable bowel syndrome patients following fecal microbiota transplantation does not improve symptoms. Gut Microbes. 2021;13(1):1–16.
Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908–17.
Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M et al. Bowel Disorders Gastroenterol. 2016.
DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, et al. Drug-resistant E. Coli Bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381(21):2043–50.
Barbara G, Ianiro G. Faecal microbial transplantation in IBS: ready for prime time? Gut. 2020;69(5):795–6.
Camilleri M. FMT in IBS: a call for caution. Gut. 2021;70(2):431.
El-Salhy M. FMT in IBS: how cautious should we be? Gut. 2021;70(3):626–8.
Liu Y, Zhang L, Wang X, Wang Z, Zhang J, Jiang R, et al. Similar fecal microbiota signatures in patients with diarrhea-predominant irritable bowel syndrome and patients with Depression. Clin Gastroenterol Hepatol. 2016;14(11):1602–11. e5.